Results 71 to 80 of about 721 (146)

Nanoparticle Drug Delivery Systems for Atherosclerosis: Precision Targeting, Inflammatory Modulation, and Plaque Stabilization

Advanced Science, Volume 12, Issue 36, September 25, 2025.
This review first summarizes the complex pathogenesis of atherosclerosis and outlines the limitations of conventional therapies. It then explores innovative nanoparticle drug delivery system (NDDS) developments, detailing their precision targeting strategies, responsiveness to plaque‐specific stimuli, modulation of key pathological processes, and ...
Yunqi Zhang, Feifei Li, Libo Liu, Ziyu An, Hanzhong Luo, Huan Zhang, Rui Ma, Ruoxi Zhang, Qiong Dai, Mingduo Zhang, Jinfan Tian, Chaoyong Liu, Xiantao Song, Yunfeng Lu   +13 more
wiley   +1 more source

In vitro inhibition of snake venom toxins by varespladib, marimastat, nafamostat and dimercaprol

Toxicon
Snakebite envenoming causes more than 130,000 deaths and more than 400,000 disabilities per year and has been classified as a priority Neglected Tropical Disease by the World Health Organization (WHO). While antivenom therapy remains the mainstay of snakebite treatment, small molecule therapeutics (SMTs) have been proposed as potential adjuncts to ...
Anandie le Roux, Stephanus J. Cloete, Jacobus P. Petzer, Anél Petzer   +3 more
openaire   +2 more sources

Temporal associations of plasma levels of the secreted phospholipase A2 family and mortality in severe COVID‐19

European Journal of Immunology, Volume 54, Issue 6, June 2024.
sPLA2 isoforms with a similar temporal pattern to sPLA2‐IIA: sPLA2‐IB, IIC, V, X, and XVI sPLA2 isoforms with an inverse temporal pattern to sPLA2‐IIA: sPLA2‐IID and XIIB. Abstract Previous research suggests that group IIA‐secreted phospholipase A2 (sPLA2‐IIA) plays a role in and predicts lethal COVID‐19 disease.
Eric Lu, Aki Hara, Shudong Sun, Brian Hallmark, Justin M. Snider, Michael C. Seeds, Joseph C. Watkins, Charles E. McCall, Hao Helen Zhang, Guang Yao, Floyd H. Chilton   +10 more
wiley   +1 more source

Anticoagulant activity in Australasian elapid snake venoms and neutralisation with antivenom and varespladib

Toxicon
The venoms of Australasian elapid snakes are known to possess coagulant activity, including some with strong procoagulant activity and others with anticoagulant activity, although the latter are less well known. This study investigates the anticoagulant activity of Australasian elapid snake venoms, and whether this activity is neutralised by commercial
Kate Murphy, Theo Tasoulis, Nathan Dunstan, Geoffrey K. Isbister   +3 more
openaire   +2 more sources

Interactions of small molecule inhibitors with secreted phospholipase A2: A review of the structural data

Chemical Biology &Drug Design, Volume 103, Issue 2, February 2024.
Due to their roles in inflammation, the sPLA2 enzymes are of much medicinal interest. sPLA2 inhibitors have been developed for the treatment of inflammatory and other conditions such as cardiovascular disease, arteriosclerosis and rheumatoid arthritis.
Chantalle Crous, Anél Petzer, Jacobus P. Petzer   +2 more
wiley   +1 more source

Study of the cytotoxic effect of secretory phospholipase A₂ of Vipera nikolskii venom on the model of HeLа and ECV340 cell lines

Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова
Snake venoms have long been the subject of research in order to obtain new antitumor compounds. Snake secretory phospholipase A2 has cytotoxic properties that are realized through different mechanisms depending on the enzyme structure and cell type. HeLa
M. A. Solovyeva, L. V. Galebskaya, M. A. Galkin, O. S. Shemchuk, V. V. Sharoyko, L. V. Vasina   +5 more
doaj   +1 more source

The Role of Secretory Phospholipase A2 (sPLA2) Inhibitor Varespladib in Mitigation of Acetaminophen(APAP) Induced Acute Liver Failure

, 2017
INTRODUCTION:Progression of acute liver injury continues long after most of the toxicant has been eliminated from the body. sPLA2 has been previously shown to mediate this progressive phase of injury.
Bhave, Vishakha, Gajjar, Nisha
core   +1 more source

The Urgent Need to Develop Novel Strategies for the Diagnosis and Treatment of Snakebites

Toxins, 2019
Snakebite envenoming (SBE) is a priority neglected tropical disease, which kills in excess of 100,000 people per year. Additionally, many millions of survivors also suffer through disabilities and long-term health consequences. The only treatment for SBE,
Harry F. Williams, Harry J. Layfield, Thomas Vallance, Ketan Patel, Andrew B. Bicknell, Steven A. Trim, Sakthivel Vaiyapuri   +6 more
doaj   +1 more source

Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury.

, 2011
Secretory phospholipase A2 (sPLA2), which links surfactant catabolism and lung inflammation, is associated with lung stiffness, surfactant dysfunction, and degree of respiratory support in acute respiratory distress syndrome and in some forms of neonatal
Zuppi, Cecilia, De Luca, Daniele, Capoluongo, Ettore Domenico, Conti, Giorgio   +3 more
core  

Partial efficacy of a Brazilian coralsnake antivenom and Varespladib to neutralize distinct toxic effects induced by a sublethal Micrurus dumerilii carinicauda envenoming in rats

, 2022
In this work, we reported the efficacy of a combination of Brazilian therapeutic coralsnake antivenom (CAV) and varespladib (phospholipase A2 inhibitor – VPL) in partially neutralizing selected toxic effects of Micrurus dumerilii carinicauda coralsnake ...
Giuffrida, Rogério, Hyslop, Stephen, Lobo, Luís G. G., Silva, Elisangela O., Quadros, Luiz H. B., Gaspar, Matheus Z., Santarém, Cecília L., Lomonte, Bruno, Silva, Nelson J., Floriano, Rafael Stuani, Silva Carvalho, Rosimeire, Gerez, Juliana Rubira   +11 more
core   +1 more source